Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (January 2022)
35 slides from Optiscan Imaging's shareholder meeting presentation, Jan 20, 2022
Slide 1: Annual General Meeting
Annual General Meeting Thursday, 20 January 2022 at 11.00am (AEDT)
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 17 January 2021. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor ma
Slide 3: Notice
Notice Not an offer or financial product advice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure doc
Slide 4: Agenda
Agenda 1. Welcome & Opening 2. Introductions 3. Apologies 4. Notice of Meeting 5. Format of Meeting 6. Chairman's Address 7. CEO/Managing Director’s Presentation 8. General Questions 9. Voting Procedure 10. Items of Business 11. Proxies 12. Financial Statements & Reports 13. Resolutions
Slide 5: Chairman’s Address
Chairman’s Address Mr Robert Cooke, Non-Executive Chairman
Slide 6: Optiscan Board
Optiscan Board Robert Cooke Camile Farah Phil Currie Ron Song Karen Borg
Slide 7: Chairman’s Address
Chairman’s Address • 2021 was a year of significant progress for Optiscan from both a commercial and governance prospective • Optiscan’s technology has the potential to the change standard of care for human cancer screening and surgery which is well recognised by medical community • Significant Boar
Slide 8: Chairman’s Address
Chairman’s Address • In the last six months the Board undertook a company wide review which included a number of internal and external presentations – the findings from this review will form the basis to finalise our operational and strategic focus going forward under the new Board and Management •
Slide 9: Managing Director’s Report
Managing Director’s Report Prof Camile Farah, PhD MBA MAICD FAIM CEO & Managing Director
Slide 10: Optiscan - Optimising for Growth
Optiscan - Optimising for Growth Key Themes • Technology is proven and differentiated • Clinical studies are providing opportunity to expand application footprint • Innovation and clinical data will accelerate market entry into USA
Slide 11: Optiscan - Global leader in endomicroscopic imaging
Optiscan - Global leader in endomicroscopic imaging Differentiated Application Market Technology Opportunities Expansion Clinical device World-leading Strong balance sheet (InVivage®) well miniaturized imaging and shareholder progressed down FDA technology support approval pathway Clinical studies H
Slide 12: Unique ability to image different tissues
Unique ability to image different tissues Cervix Gastric Oral Kidney Lung Eye Blood vessel Tendon
Slide 13: Proven ability to differentiate cancer vs normal
Proven ability to differentiate cancer vs normal Oesophagus Colon Brain Breast Oesophageal cancer Adenocarcinoma Glioblastoma Ductal carcinoma
Slide 14: Excellent correlation with current gold standard histopathology
Excellent correlation with current gold standard histopathology Endometrium Mesothelioma Pituitary adenoma Oral carcinoma in situ
Slide 15: Strong Relationships and Partnerships
Strong Relationships and Partnerships Established relationships with leading global medical technology companies, universities and hospitals Oral/head and neck cancer Breast cancer study at studies leading Melbourne hospitals • Leaders in neurosurgery with digital pathology workflow recently approve
Slide 16: Selected 2021 publications demonstrating Optiscan technology
Selected 2021 publications demonstrating Optiscan technology Brain Brain Brain Redosing of Fluorescein Sodium Improves Image Socio-Organizational Impact of Confocal Laser Confocal Laser Microscopy in Neurosurgery: Interpretation During Intraoperative Ex Vivo Confocal Endomicroscopy in Neurosurgery a
Slide 17: Optiscan – Positioned for unique clinical impact
Optiscan – Positioned for unique clinical impact Patients & Clinicians & Markets & Advocates hospital healthcare executives sector Enhanced accuracy of Reduced Increased decision negative demand, making and impacts and maturity and outcomes cost savings readiness Optiscan Digital platform Ability fo
Slide 18: Differentiated research and clinical devices for market diversification
Differentiated research and clinical devices for market diversification FIVE2 InVivage® Research Device Clinical Device
Slide 19: FIVE2 Sales, Rentals and Loans
FIVE2 Sales, Rentals and Loans FIVE2 sales achieved FIVE2 units on site FIVE2 demos in progress
Slide 20: InVivage® Clinical Device
InVivage® Clinical Device Overview • Miniaturized hand-held rigid probe (4mm diameter tip) • Real-time, sub-cellular live microscopic imaging • High resolution images, 1000x real magnification • Advanced software user interface • DICOM-compatible/PACS-enabled • Targeting cancer screening and surgica
Slide 21: InVivage® FDA submission process update
InVivage® FDA submission process update FDA approval process • InVivage 510(k) submission through the FDA reduced timeframe pathway • Aim to receive approval for use of images by clinicians, paving the way for follow-up FDA approval • Submission to take place once all validation, verification and cl
Slide 22: Key Achievements in 2021 (1/2)
Key Achievements in 2021 (1/2) ✓ Strengthening leadership ✓ Accelerating preparation ✓ Progression of US market and Board capabilities for FDA application for entry planning InVivage approval in the US • Appointment of Mr Robert Cooke, Ms Karen Borg and Mr Ron Song • Engagement with potential to Boa
Slide 23: Key Achievements in 2021 (2/2)
Key Achievements in 2021 (2/2) ✓ Ongoing clinical studies to ✓ Completion of imaging for ✓ Sales of 2 FIVE2 systems to support oral/head & neck Breast Cancer Margin leading Australian clinical applications Assessment study Research Institutions • Completed patient recruitment • Swinburne University
Slide 24: FY21 Financial Highlights
FY21 Financial Highlights ✓ Strengthened balance ✓ FY21 Total Income ✓ FY21 EBITDA of ($1.85m); sheet through a capital (operating revenue and FY21 Net operating cash raising of $9.8m other income) of $2.54m, outflow of ($2.13m) up ~28% on FY20 • Backing of Clermont Group as • Spending to underpin f
Slide 25: Oral Cancer study at Melbourne Dental School (1/2)
Oral Cancer study at Melbourne Dental School (1/2) Results will assist with InVivage® FDA submission and open up clinical applications and markets Summary • Triage and monitor oral tissue health and escalate the diagnosis of oral cancer Aims • Validate use of fluorescent probe and mouth map software
Slide 26: Oral Cancer study at Melbourne Dental School (2/2)
Oral Cancer study at Melbourne Dental School (2/2) Comparison of oral imaging using three dyes • Using Optiscan technology, clinically abnormal areas can Normal be identified as either precancerous or Dr Tami Yap, University of Melbourne cancerous compared to normal tissue • Multiple potential dye a
Slide 27: Oral Screening study at Australian Centre for Oral Oncology (1/2)
Oral Screening study at Australian Centre for Oral Oncology (1/2) Results will assist with development of machine learning and artificial intelligence algorithms for diagnostic applications Summary • Image a range of oral lesions (cancer, precancer, benign) compared to normal Aims • Determine accura
Slide 28: Oral Screening study at Australian Centre for Oral Oncology (2/2)
Oral Screening study at Australian Centre for Oral Oncology (2/2) Oral screening: Optiscan CLE technology vs. Histopathology • Using Optiscan Prof Camile Farah, Australian Centre for Oral Oncology Research & Education Normal technology, oral cancer can be differentiated from precancer and normal tis
Slide 29: Breast Cancer Margin Assessment study (1/2)
Breast Cancer Margin Assessment study (1/2) Results from the breast study will open up a new clinical application and market offering Summary • Determine if intraoperative imaging of excised breast tissue can detect positive surgical margins Aim compared to standard pathology Key • Professor Bruce M
Slide 30: Breast Cancer Margin Assessment study (2/2)
Breast Cancer Margin Assessment study (2/2) Invasive Carcinoma of the Breast: Optiscan CLE technology vs. Histopathology • Optiscan images mirror the current gold standard Individual cells (0.5mm x 0.5mm) • Optiscan technology can provide precise identification of cancer cells at surgery • Future cl
Slide 31: Optiscan - Immediate Priorities
Optiscan - Immediate Priorities • Accelerate FDA approval of InVivage® 1 • Progress focused US launch • Enhance product functionality 2 • Drive product R&D • Expand clinical applications 3 • Drive sales revenue through market growth
Slide 32: Optiscan - Future Perspectives
Optiscan - Future Perspectives • Expand development of InVivage® platform 1 • Advance miniaturization and dye alternatives 2 • Explore molecular imaging applications • Target artificial intelligence applications1 3 • Drive AI-related diagnostics2 1. Source: McKinsey 2020 2. Source: BCG 2019
Slide 33: Optiscan – Towards global leadership in medical imaging & diagnostics
Optiscan – Towards global leadership in medical imaging & diagnostics World leading cutting edge patent-protected technology Strong runway to progress Real-time in vivo imaging for platform-based workflow cancer diagnosis and solutions for clinical practice surgery Well funded Mature market balance
Slide 34: Thank You
[| Question & Answer Thank You (brtiscen
Slide 35: Thank you for your attendance
Thank you for your attendance
Optiscan Imaging — Shareholder Meeting (January 2022) on 6ix